AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on ...

AstraZeneca has discontinued its CAPItello-280 phase three trial assessing Truqap, or capivasertib, in combination with docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic ...

The UK regulator has said eligible patients with prostate cancer will get early ... after three or more prior anti-androgen and chemotherapy regimens. "With over 11,500 prostate cancer deaths ...

Credit: Getty Images The 2024 US Prostate Cancer Conference published 34 consensus ... aggressive therapy and who needs less. Who needs chemo and who doesn’t? These are answerable questions ...

HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic nucleotide analogue that kills nearby cancer cells. Together, this regimen is designed to induce an ...

Pedro C. Barata, MD, MSc, discusses the use of darolutamide in patients with hormone-sensitive prostate cancer.

in mCRPC patients previously treated with hormonal therapy and chemo. Merck’s run of bad results is unfortunately par for the course for checkpoint inhibitors in prostate cancer, with other ...

Lenny Santoro credits NIH research with saving his life longer than doctors expected. Duke Health's Dr. Daniel George warns ...

Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...